Free Trial

10 Best Small Cap Stocks to Buy Now - 6 of 10

 
 

Q32 Bio (NASDAQ:QTTB)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$72.33 (119.5% Upside)

About Q32 Bio

Q32 Bio logoQ32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/24/2024Raymond JamesInitiated CoverageStrong-Buy$90.00
9/11/2024Wells Fargo & CompanyInitiated CoverageOverweight$95.00
6/17/2024GuggenheimInitiated CoverageBuy$100.00
5/21/2024Leerink PartnrsUpgradeStrong-Buy
5/21/2024Leerink PartnersInitiated CoverageOutperform$54.00
4/11/2024OppenheimerInitiated CoverageOutperform$50.00
4/2/2024Piper SandlerInitiated CoverageOverweight$45.00
 

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Click Here For Your Free Guide